Harnessing off-target effects

Gaye Saginc; Franziska Voellmy; Rune Linding

doi:10.1038/nchembio.2519

Harnessing off-target effects

Gaye Saginc, Franziska Voellmy, Rune Linding

Department of Biotechnology and Biomedicine

University of Copenhagen

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule screening in non-small-cell lung cancer to repurpose an FDA-approved ALK/IGF1R inhibitor and uncover its mechanism of action.

Original language	English
Journal	Nature Chemical Biology
Volume	13
Issue number	12
Pages (from-to)	1204-1205
Number of pages	2
ISSN	1552-4450
DOIs	https://doi.org/10.1038/nchembio.2519
Publication status	Published - 2017

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nchembio.2519

OpenUrl availability

Full text

Cite this

@article{9c6402a3b3364013975321989bbeb072,

title = "Harnessing off-target effects",

abstract = "The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule screening in non-small-cell lung cancer to repurpose an FDA-approved ALK/IGF1R inhibitor and uncover its mechanism of action.",

author = "Gaye Saginc and Franziska Voellmy and Rune Linding",

year = "2017",

doi = "10.1038/nchembio.2519",

language = "English",

volume = "13",

pages = "1204--1205",

journal = "Nature Chemical Biology",

issn = "1552-4450",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Harnessing off-target effects

AU - Saginc, Gaye

AU - Voellmy, Franziska

AU - Linding, Rune

PY - 2017

Y1 - 2017

N2 - The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule screening in non-small-cell lung cancer to repurpose an FDA-approved ALK/IGF1R inhibitor and uncover its mechanism of action.

AB - The 'off-targets' of a drug are often poorly characterized yet could be harnessed in the treatment of complex diseases. A recent study used a small-molecule screening in non-small-cell lung cancer to repurpose an FDA-approved ALK/IGF1R inhibitor and uncover its mechanism of action.

U2 - 10.1038/nchembio.2519

DO - 10.1038/nchembio.2519

M3 - Journal article

C2 - 29161245

SN - 1552-4450

VL - 13

SP - 1204

EP - 1205

JO - Nature Chemical Biology

JF - Nature Chemical Biology

IS - 12

ER -

Harnessing off-target effects

Abstract

UN SDGs

Access to Document

OpenUrl availability

Fingerprint

Cite this